Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders

References

• Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin. Thromb. Hemost.33, 759–770 (2007).
   PubMedGoogle Scholar
• Roix J, Misteli T. Genomes, proteomes, and dynamic networks in the cell nucleus. Histochem. Cell Biol.118, 105–116 (2002).
   PubMedGoogle Scholar
• Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev.122, 945–962 (2001).
   PubMed Web of Science ®Google Scholar
• Dalle-Donne I, Scaloni A, Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction And Diseases. Dalle-Donne I, Scaloni A, Butterfield DA (Eds). John Wiley & Sons, Hoboken, NJ , USA (2006).
   Google Scholar
• Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic. Biol. Med.43, 658–777 (2007).
   PubMed Web of Science ®Google Scholar
• Sultana R, Boyd-Kimball D, Poon HF et al. Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging27, 1564–1576 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Gnjec A, Poon HF et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J. Alzheimers Dis.10, 391–397 (2006).
   PubMed Web of Science ®Google Scholar
• Opii WO, Joshi G, Head E et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease. Neurobiol. Aging29, 51–70 (2008).
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med.33, 562–571 (2002).
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Thongboonkerd V et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, α-enolase and heat shock cognate 71. J. Neurochem.82, 1524–1532 (2002).
   PubMed Web of Science ®Google Scholar
• Poon HF, Calabrese V, Calvani M, Butterfield DA. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by l-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid. Redox Signal.8, 381–394 (2006).
   PubMed Web of Science ®Google Scholar
• Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res.29, 2215–2220 (2004).
   PubMed Web of Science ®Google Scholar
• Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice – a model of familial Parkinson’s disease. Neurobiol. Dis.18, 492–498 (2005).
   PubMed Web of Science ®Google Scholar
• Poon HF, Hensley K, Thongboonkerd V et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice – a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med.39, 453–462 (2005).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer’s disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis.12, 61–72 (2007).
   PubMed Web of Science ®Google Scholar
• Mosconi L, De Santi S, Li Y et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging33, 210–221 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt A, Schonknecht P, Henze M, Seidl U, Haberkorn U, Schroder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer’s disease. Psychiatry Res.155, 147–154 (2007).
   PubMedGoogle Scholar
• Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration. J. Neurochem.86, 1313–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Perluigi M, Fai Poon H, Hensley K et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice – a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med.38, 960–968 (2005).
   PubMed Web of Science ®Google Scholar
• Reed T, Perluigi M, Sultana R et al. Redox proteomics identification of 4-hydroxy-2-nonenal-modified proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis.30, 107–120 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou T, Cao R et al. Evaluation of the application of sodium deoxycholate to proteomic analysis of rat hippocampal plasma membrane. J. Proteome Res.5, 2547–2553 (2006).
   PubMed Web of Science ®Google Scholar
• Rabilloud T, Luche S, Santoni V, Chevallet M. Detergents and chaotropes for protein solubilization before two-dimensional electrophoresis. Methods Mol. Biol.355, 111–119 (2007).
   PubMedGoogle Scholar
• Molloy MP. Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem.280, 1–10 (2000).
   PubMed Web of Science ®Google Scholar
• Ruan Y, Wan M. An optimized procedure for solubilization, reduction, and transfer of human breast cancer membrane-enriched fraction by 2-DE. Electrophoresis28, 3333–3340 (2007).
   PubMed Web of Science ®Google Scholar
• Twine SM, Mykytczuk NC, Petit M et al. Francisella tularensis proteome: low levels of ASB-14 facilitate the visualization of membrane proteins in total protein extracts. J. Proteome Res.4, 1848–1854 (2005).
   PubMedGoogle Scholar
• Zischka H, Gloeckner CJ, Klein C, Willmann S, Swiatek-de Lange M, Ueffing M. Improved mass spectrometric identification of gel-separated hydrophobic membrane proteins after sodium dodecyl sulfate removal by ion-pair extraction. Proteomics4, 3776–3782 (2004).
   PubMedGoogle Scholar
• Matt P, Fu Z, Fu Q, Van Eyk JE. Biomarker discovery: proteome fractionation and separation in biological samples. Physiol. Genomics33(1), 12–17 (2008).
   PubMed Web of Science ®Google Scholar
• Ferguson PL, Smith RD. Proteome analysis by mass spectrometry. Annu. Rev. Biophys. Biomol. Struct.32, 399–424 (2003).
   PubMedGoogle Scholar
• Haqqani AS, Hutchison JS, Ward R, Stanimirovic DB. Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS. J. Neurotrauma24, 54–74 (2007).
   PubMedGoogle Scholar
• Lopez JL. Two-dimensional electrophoresis in proteome expression analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.849, 190–202 (2007).
   PubMed Web of Science ®Google Scholar
• Orchard S Proteomics: from technology development to biomarker applications. Expert Rev. Proteomics4, 709–710 (2007).
   PubMedGoogle Scholar
• Klase ZA, Van Duyne R, Kashanchi F. Identification of potential drug targets using genomics and proteomics: a systems approach. Adv. Pharmacol.56, 327–368 (2008).
   PubMedGoogle Scholar